Rubella (German Measles)¶

Chapter 212 | Part 5: Infectious Diseases · Part 5 – Infectious Diseases: Viral (incl. HIV) · Chapter 212

Key Clinical Points¶

The classic triad of Congenital Rubella Syndrome (CRS)—cataracts, hearing impairment, and heart defects—is seen in only ~10% of infants with CRS.
Acquired rubella rash typically lasts up to 3 days and is often subclinical (up to 50% of cases).
Lymphadenopathy, particularly occipital and postauricular, is a hallmark sign appearing during the second week after exposure.
Risk of CRS is 90% if maternal infection occurs during the first 10 weeks of gestation; risk declines with later infection.
No specific antiviral therapy exists; management is symptomatic.
Immunoglobulin does not prevent rubella infection after exposure and is not recommended for routine postexposure prophylaxis.
In the US, interruption of endemic rubella transmission was achieved by 2001; current cases are primarily importations.
Rubella IgM antibodies may be detectable for up to 6 weeks in acquired infection and up to 1 year in congenital infection.
Vaccination with MMR (measles, mumps, rubella) is the most effective prevention; two doses recommended at 12–15 months and 4–6 years.
Women of childbearing age should be vaccinated before pregnancy; avoid pregnancy for 28 days after receiving RCV.

1. DEFINITION & OVERVIEW¶

• Rubella: Historically known as German measles; a viral infection caused by the rubella virus. • Congenital Rubella Syndrome (CRS): - Definition: The constellation of severe birth defects resulting from maternal infection during pregnancy.

1.1 Virus Classification¶

• Family/Genus: Matonaviridae, Rubivirus. • Structure: Single-strand RNA enveloped virus (40–80 nm diameter). • Genome: ~10-kb positive-sense RNA. • Proteins: Core protein and single-layer lipoprotein envelope with E1 and E2 glycoproteins. • Host/Type: Humans are the only known reservoir; only one antigenic type exists.

2. EPIDEMIOLOGY¶

• General Status: Shifted significantly due to vaccination; transmission interrupted in US but importations continue.

2.1 United States History¶

• 1964–1965 Epidemic: 12.5 million cases → ~20,000 cases of CRS. • Post-1969 Vaccination: Cases dropped by >99%. • Coverage: >90% for children 19–35 months since 1996. • Endemic Status: Declared no longer endemic in 2004; transmission interrupted by 2001. • Recent Cases (2010–2022): 66 cases reported; 71% in ages 20–49 (including women of childbearing age). • CRS Cases: 13 cases reported, all from foreign-born mothers.

2.2 Global Epidemiology¶

• Case Decline: ~700,000 cases in 2000 → 17,407 in 2022 (underestimated due to mild symptoms/lack of reporting). • Vaccination Gap: 25% of world's children remained unvaccinated in 2022. • CRS Burden: ~105,000 cases of CRS annually globally in 2010. • WHO Goals: 5 of 6 regions have rubella elimination goals; 90% of countries recommend RCV in routine schedules.

2.3 CRS Incidence & Impact¶

• Pre-Vaccine Era: 0.1–0.2 cases per 1,000 live births (endemic) → 1–4 cases per 1,000 (epidemic). • 1964–1965 Epidemic Impact: >30,000 infections during pregnancy; ~20,000 infants born alive with CRS. • Disability Stats: >11,000 deaf, >3,500 blind, ~2,000 with intellectual disability. • Economic Cost: Epidemic cost >$1.5 billion; lifetime medical costs for CRS range from 11,255 (low-income) to 934,000 (high-income).

3. ETIOLOGY & PATHOPHYSIOLOGY¶

• Transmission: Respiratory droplets. • Pathogen Route: Nasopharynx → Lymph nodes → Viremia → Placenta (in pregnant women). • Fetal Impact: Placental replication leads to infection of fetal organs; results in chronic infection for up to 1 year after birth.

3.1 Pathogenesis of Acquired Rubella¶

• Pathogen Route: Nasopharynx → Lymph nodes → Viremia. • Shedding: Individuals with acquired rubella may shed virus from 7 days before rash onset to ~5–7 days thereafter.

3.2 Pathogenesis of CRS¶

• Timing: Most severe consequences occur during first trimester. • Outcomes: Miscarriage, fetal death, premature delivery, or live birth with defects. • Common Defects: Eyes, ears, and heart. • Transient Manifestations: Thrombocytopenia with purpura/petechiae (e.g., 'blueberry muffin syndrome'). • Infection without CRS: Some infants have congenital infection but no apparent signs; termed 'infants with congenital rubella virus infection only.' • Fetal Infection Duration: Chronic infection persists for up to 1 year after birth.

4. CLINICAL FEATURES¶

• Acquired Rubella: - Maculopapular rash (usually <3 days); 50% of cases are subclinical. - Younger children: Rash is first sign. - Older children/adults: 1–5 day prodrome (fever, malaise, UR symptoms) → rash. - Lymphadenopathy: Occipital and postauricular; noted in 2nd week after exposure. - Adult complications: Common arthralgia/arthritis (especially women); less common thrombocytopenia/encephalitis. • Congenital Rubella Syndrome (CRS): - Classic triad (cataracts, hearing impairment, heart defects) seen in only ~10% of cases. - Hearing impairment is the most common single defect.

4.3 CRS Manifestations¶

• Clinical Presentation: Often non-specific; requires lab confirmation to distinguish from other intrauterine infections. • Table 212-1: Common Transient and Permanent Manifestations in Infants with Congenital Rubella Syndrome - Transient: Hepatosplenomegaly, Interstitial pneumonitis, Thrombocytopenia with purpura/petechiae (e.g., dermal erythropoiesis or "blueberry muffin syndrome"), Hemolytic anemia, Bony radiolucencies, Intrauterine growth retardation, Adenopathy, Meningoencephalitis. - Permanent: Hearing impairment/deafness, Congenital heart defects (patent ductus arteriosus, pulmonary arterial stenosis), Eye defects (cataracts, cloudy cornea, microphthalmos, pigmentary retinopathy, congenital glaucoma), Microcephaly, Central nervous system sequelae (mental and motor delay, autism).

5. DIFFERENTIAL DIAGNOSIS¶

• Acquired Rubella Mimics: Scarlet fever, roseola, toxoplasmosis, fifth disease, measles, Zika. • CRS Differential: Most features are non-specific; may be associated with other intrauterine infections.

6. INVESTIGATIONS & DIAGNOSIS¶

Laboratory assessment of rubella virus infection is conducted by serologic and virus detection methods.

6.1 Acquired Rubella Diagnosis¶

Serologic Testing:
IgM detection in acute-phase serum.
OR 4-fold rise in IgG titer between acute (7–10 days post-onset) and convalescent (~14–21 days later) specimens.
Note: If IgM is negative before day 5 after rash onset, serologic testing should be repeated.
Avidity Testing:
Used to distinguish primary infection from reinfection.
Low-avidity = recent infection; High-avidity (mature) = infection ≥ 2 months ago.
Viral Detection:
Nasopharyngeal, throat, or urine samples.
Best collected 1–3 days after symptom onset; no later than 7 days.

6.2 CRS Diagnosis¶

Serologic Assays:
IgM detection: Present for up to 6 months, detectable up to 1 year post-birth.
Rule of Thumb: If IgM is negative at birth but symptoms exist, retest at 1 month.
IgG Titer: Persistence beyond expected decay (2-fold/month) indicates congenital infection.
Virus Detection:
Nasopharyngeal and throat swabs; urine.
Most likely positive if obtained within first 6 months after birth.

6.3 Diagnosis in Pregnant Women¶

Screening: Routine rubella IgG screening for immunity.
Interpretation:
Positive IgG → Immune.
Negative IgG → Susceptible; test for IgM if exposed.
Confirmation of Timing:
If IgM positive, confirm with low-avidity IgG to determine if infection occurred during pregnancy.
Risk Assessment:
Risk of CRS: 90% if infection ≤ 10 weeks.
Risk declines after 16 weeks (except hearing, which can occur up to 20 weeks).
Exclusion Criteria:
Rubella IgM antibody testing is not recommended for pregnant women with no history of illness or with contact with a rubella-like illness.

7. MANAGEMENT & TREATMENT¶

Acquired Rubella:
No specific antiviral therapy.
Symptomatic treatment for fever and arthralgia.
Immunoglobulin (IG) Prophylaxis:
Not recommended for routine postexposure prophylaxis; does not prevent infection.

Pregnancy Monitoring¶

• Clinical Monitoring: Required for women with evidence of acute infection. - Determine gestational age to assess risk. - Risk of CRS: 90% if infection ≤ 10 weeks; risk declines after 16 weeks (except hearing, which can occur up to 20 weeks).

8. SPECIAL POPULATIONS¶

• Vaccination Strategy: - Most effective prevention for both acquired and CRS. - Two doses recommended: 1st at 12–15 months; 2nd at 4–6 years. • Pregnancy & Vaccination: - Women of childbearing age should be vaccinated before pregnancy. - Contraindication: Do not give RCV to known pregnant women. - Post-Vaccine Window: Avoid pregnancy for 28 days after receiving RCV.

9. KEY PEARLS & HIGH-YIELD POINTS¶

• Timing is Critical: 90% risk of CRS if infection occurs within the first 10 weeks. • Clinical Nuance: 50% of cases are subclinical; don't assume absence of rash means no infection. • Diagnostic Window: IgM can be detected for up to 6 weeks in adults but up to 1 year in infants with CRS. • Avidity Testing: Essential tool for determining if a pregnant woman's infection is recent (low-avidity) or old (high-avidity).

Reference Tables¶

TABLE 212-1 Common Transient and Permanent Manifestations in Infants with Congenital Rubella Syndrome¶

Harrison's 22e, p.1644

TRANSIENT MANIFESTATIONS	PERMANENT MANIFESTATIONS
Hepatosplenomegaly Interstitial pneumonitis Thrombocytopenia with purpura/ petechiae (e.g., dermal erythropoiesis or “blueberry muffin syndrome”) Hemolytic anemia Bony radiolucencies Intrauterine growth retardation Adenopathy Meningoencephalitis	Hearing impairment/deafness Congenital heart defects (patent ductus arteriosus, pulmonary arterial stenosis) Eye defects (cataracts, cloudy cornea, microphthalmos, pigmentary retinopathy, congenital glaucoma) Microcephaly Central nervous system sequelae (mental and motor delay, autism)